Loading stock…

Novo Nordisk A/S (NVO) Stock Verdict & Ratings | Investment Bastion

02Growth

Is it actually growing, and how fast?

NVONovo Nordisk A/S

Revenue FY25$48.5B

GROWTH RATING↗

VERY WEAK13 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+24%9

Revenue, next 1Y-8%1

Revenue, next 3Y, CAGR+1%1

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-8%3

EPS growth, FY27E-2%3

EPS growth, FY28E+6%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 24%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

WATCH

Revenue grew 24%/yr over the last 3 years; forecasts see it cooling to 0.8%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 87% of companies worldwide.

Revenue is set to grow 0.8%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

Earnings are set to fall even as revenue grows (EPS about -2%/yr vs revenue 0.8%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

NVONovo Nordisk A/S

Total return Current149%

Price return Current109%

MOMENTUM RATING↗

VERY WEAK2 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-19%1

3-month return-24%1

YTD return-24%2

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return-34%1

3-year return-57%1

5-year return-17%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-57% over three years and -17% over five), behind 80% of the market.

It's down 34% over the past year, now 40% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-19%), over three months (-24%) and so far this year (-24%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Novo Nordisk. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

NVONovo Nordisk A/S

Revenue FY25$48.5B

GROWTH RATING↗

VERY WEAK13 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+24%9

Revenue, next 1Y-8%1

Revenue, next 3Y, CAGR+1%1

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-8%3

EPS growth, FY27E-2%3

EPS growth, FY28E+6%6

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 24%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

WATCH

Revenue grew 24%/yr over the last 3 years; forecasts see it cooling to 0.8%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 87% of companies worldwide.

Revenue is set to grow 0.8%/yr over the next 3 years, behind most of the market.2/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

Earnings are set to fall even as revenue grows (EPS about -2%/yr vs revenue 0.8%/yr).

BOTTOM LINE

Stalled Business

Growth is a weak point here: a business that is slowing. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

NVONovo Nordisk A/S

Total return Current149%

Price return Current109%

MOMENTUM RATING↗

VERY WEAK2 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-19%1

3-month return-24%1

YTD return-24%2

MID & LONG-TERM▾SCORE

% of 52-week high60%2

1-year return-34%1

3-year return-57%1

5-year return-17%3

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-57% over three years and -17% over five), behind 80% of the market.

It's down 34% over the past year, now 40% below its 52-week high. That is lagging the market.

The stock is underperforming over the past month (-19%), over three months (-24%) and so far this year (-24%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Novo Nordisk. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Novo Nordisk A/S

01Key Ratings

02Growth

03Price Momentum

04Value

Stop guessing on Novo Nordisk. Get the full investment case.

Premium

02Growth

03Price Momentum

04Value

Stop guessing on Novo Nordisk. Get the full investment case.

Premium